Macquarie Capital’s Pharma and Healthcare Research Analyst Kunal Dhamesha names Lupin his top pick on de-risked earnings and GLP-1 potential, flags hospital stocks on capacity-led profit risks, and sees upside for Indian CDMOs if the US clamps down on Chinese rivals under the Biosecure Act.
